Predictors and prognosis of intrauterine and intrapartum human immunodeficiency virus (HIV) transmission were investigated among 432 children of HIV-infected women in the Perinatal AIDS Collaborative Transmission Study. Timing of transmission was inferred from polymerase chain reaction or viral culture within 2 days of birth. Proportions of infections due to intrauterine transmission were similar among women using (29%) or not using zidovudine (30%). Preterm delivery was strongly associated with intrapartum transmission (relative risk, 3.7; 95% confidence interval [CI], 2.2-6.1), particularly among infants delivered longer after membrane rupture, but was not associated with intrauterine transmission. Progression to AIDS or death increased 2.5-fold (95% CI, 1.1-5.8) among intrauterine infected children, adjusting for preterm delivery, and maternal CD4 cell count. Early transmission appears unlikely to explain instances of zidovudine failure. Preterm infants may be more vulnerable to HIV acquisition at delivery, especially if membrane rupture is prolonged. Intrauterine infection does not appear to increase risk of preterm delivery.
The timing of maternal-infant human immunodeficiency virus (HIV) type 1 transmission can be inferred from the results of virus-specific diagnostic tests (mostly DNA polymerase chain reaction [PCR] or viral culture) on samples drawn near birth [1] . These tests, which have excellent diagnostic sensitivity and specificity among children, when done close to birth identify fewer than one-third of those later known to be HIV-infected [2] [3] [4] [5] [6] [7] [8] . It is assumed that in these infected newborns with negative test results, the amount of circulating virus has yet to replicate to detectable levels due to recent infection, most likely about the time of delivery. Infection detectable earlier (within 48 h of birth according to the working definition proposed to guide this thinking [1] ) is, conversely, assumed to have been acquired in utero.
Intrauterine infection has been hypothesized to cause rapidly progressive HIV disease. In a study of 150 HIV-infected chil-dren, PCR or culture positivity in the first week of life was associated with a 3-fold increased risk of severe manifestations of HIV infection [9] . Other smaller studies have also reported modest associations [5, 6, 8] , but only one report ( ) [ 10] n ϭ 8 shows an association when early infection is defined using time intervals proposed by the working definition. Since the sensitivity of PCR and culture increases rapidly in the first week of life [2, [11] [12] [13] , wider time intervals may be less able to distinguish intrauterine from intrapartum infections.
A further limitation of previous studies of timing of infection and disease progression is that they have mostly not controlled for other maternal and perinatal factors associated with prognosis. For example, advanced maternal disease and preterm delivery have both been associated with faster disease progression among infected children [14, 15] . If advanced maternal disease increases the likelihood of intrauterine transmission or if preterm delivery results from intrauterine infection, then these variables (rather than the timing of transmission) may explain prognosis. Identification of separate timing-specific risk factors for maternal-infant HIV transmission may help to clarify alternative explanations for any increases observed in the severity of disease in intrauterine-infected children.
In a large multisite study of HIV-infected children, we tested whether the timing of transmission, inferred from the results of early PCR or viral cultures in the first 2 days of life, is associated with disease progression, independent of maternal and perinatal characteristics. We also investigated the specificity of maternal and perinatal factors for either intrauterine or inDownloaded from https://academic.oup.com/jid/article-abstract/179/1/52/883150 by guest on 06 February 2019 trapartum HIV transmission. We previously showed that intrapartum characteristics, particularly duration of membrane rupture, are associated with intrapartum but not intrauterine transmission [16] , suggesting that the use of early virus-specific diagnostic tests to identify the timing of transmission may be valid. Here we extend this analysis to examine other transmission risk factors, including preterm delivery and maternal zidovudine use. Clarification of whether these risk factors affect intrauterine or intrapartum transmission may help illuminate mechanisms of transmission.
Methods
Study population. HIV-infected pregnant women and their delivered children were followed as part of the Perinatal AIDS Collaborative Transmission Study. Clinical sites in New York City, Newark, New Jersey, Baltimore, and Atlanta participate in this Centers for Disease Control and Prevention (CDC) collaborative project. Pregnant and parturient HIV-infected women were recruited at these sites from 1985 to the present. For this analysis, 432 liveborn infants who had HIV-1 DNA PCR or viral culture results available for samples drawn within 2 calendar days of birth (inclusive) were included. Children known to have been breast-fed or whose HIV status could not be determined were excluded.
Study protocol. Staff at each site collected a common set of clinical and laboratory data. Maternal clinical and interview data, collected during pregnancy and after delivery, included CD4 and CD8 T lymphocyte counts, clinical symptoms, and use of antiretroviral drugs, including zidovudine. Obstetric and neonatal data were collected for all deliveries. Maternal lymphocyte data collected during pregnancy or !1 month after delivery was used in this study.
All infants in this analysis had blood drawn within 2 calendar days of birth for laboratory analysis. Results from cord blood were not included. All children were tested again at months 1, 2, 4, and 6 and at 3-month intervals thereafter. Infected children were retained in the cohort and were examined at regular intervals according to standard protocols.
Laboratory analysis. Samples were tested for HIV DNA by PCR using methods previously described [5] . Heparin-treated blood samples were shipped at room temperature overnight for separation and storage at Ϫ70ЊC until testing. Viral cultures were done at two of the sites using standard methods [17] . Lymphocyte subset determination was performed using flow cytometry procedures.
Definitions. Children were considered infected if they were HIV-seropositive, confirmed by Western blot at у18 months of age, had two or more positive PCR tests or viral cultures at any age, had an AIDS-defining illness, or if they died with an HIVrelated condition [18] .
Intrauterine infection was presumed if a child was infected and had a positive PCR or viral culture within 2 calendar days of birth. Intrapartum infection was presumed if an infected child had negative results within this interval (adapted from the working definition [1] ).
Statistical analysis. The unit of analysis was the pregnancy. Only the first-born of multiple births was retained (all multiple births were concordant for HIV status). Siblings were retained, since analysis of these data found the outcomes of subsequent pregnancies were independent [19] . Risk factor information referred to each pregnancy separately.
Intrauterine transmission rates were calculated as the number with intrauterine infections divided by the total number of infants (marginal probability), and intrapartum transmission rates as the number with intrapartum infections divided by the number who survived without intrauterine infection, that is, only among the subgroup with early negative results (conditional probability). Intrauterine and intrapartum transmission rates were compared by perinatal and maternal characteristics using Mantel-Haenszel estimates of relative risks (RRs). Multiple logistic regression was used to estimate adjusted odds ratios (ORs) for each perinatal and maternal characteristic adjusted for the other characteristics investigated.
The probability of AIDS-free survival by results of early PCR or culture was described using Kaplan-Meier lifetable methods and tested using log-rank tests. The CDC pediatric AIDS surveillance definition was used, excluding lymphoid interstitial pneumonitis. Time from birth to AIDS diagnosis or death was calculated among children with these events; children who survived AIDS-free were censored at the age they were last seen. Proportional hazards models were used to estimate adjusted RR.
Results

HIV infection was identified in 67 (16%) of the 432 infants:
19 (28%; 95% CI, 18-41) were positive at р2 days of life, and 48 (72%; 95% CI, 59-82) were negative at this time. The risk of intrauterine transmission was 4.4% (95% CI, 2.7-6.9). The risk of intrapartum transmission was 11.6% (95% CI, 8.8-15.2). Results were similar regardless of whether infants were tested by PCR or viral culture: 398 infants had PCR results, 77 had culture results, and 43 had both (all concordant). Positive results were found in 16 (27%) of 59 infected children with early PCR results and 3 (25%) of 12 infected children with early viral culture results. At their next test, 43 (90%) of 48 infected children with negative early tests were positive; 3 children had a negative test result at ∼1 month and the remaining 2 at older ages. The cumulative probability of at least one positive PCR or viral culture result by age 1 month was 89% (95% CI, 71-100).
Risks of Intrauterine and Intrapartum HIV Transmission
Maternal zidovudine use.
Unadjusted intrapartum HIV transmission was slightly, but not significantly, lower when mothers used zidovudine during pregnancy (10%) than when they did not (13%; RR, 0.7; 95% CI, 0.4-1.3) (table 1). Adjusting for markers of severity of maternal disease (CD4 percentage and clinical status), zidovudine use was associated with a substantial and significant reduced risk of intrapartum transmission (OR, 0.3; 95% CI, 0.1-0.7) and remained significant with further adjustment for preterm delivery and duration of membrane rupture (table 2) . Maternal zidovudine use was not The study included mother-child pairs enrolled before and after demonstration of beneficial effects of zidovudine to prevent HIV transmission. Thus, it includes women who used zidovudine specifically to prevent transmission and women who took zidovudine therapeutically. At least 94% of mother-child pairs received zidovudine at one or more of the times specified by AIDS Clinical Trials Group 076 protocol (i.e., to the mother during the third trimester and at delivery; to the infant postnatally). However, only 37% of pairs received zidovudine at all three time points. Preterm delivery. Preterm infants had a substantially increased risk of intrapartum HIV infection but did not have increased risk of intrauterine HIV infection. The intrapartum HIV transmission rate was 31% among preterm infants compared with 8% among term infants (RR, 3.7; 95% CI, 2.2-6.1) (table 1). As a continuous variable, the distribution of gestational age was similar among uninfected and intrauterineinfected infants (12% of uninfected infants were born before 37 weeks vs. 21% of intrauterine-infected infants, ), but P ϭ .21 intrapartum-infected children were more likely than uninfected infants to be born earlier (40% born before 37 weeks, P ϭ ) (figure 1). The association between preterm delivery and .02 intrapartum transmission remained strong and significant after adjustment for zidovudine use, duration of membrane rupture, maternal clinical stage, and CD4 cell count (table 2) .
When further stratified by duration of membrane rupture, the association between preterm delivery and intrapartum transmission was found only among infants born longer after membrane rupture (table 3) . Among infants born у4 h after rupture of fetal membranes, 40% of preterm and 11% of term infants had intrapartum HIV transmission (RR, 3.8; 95% CI, 1.9-7.8); if born р3 h after rupture, 6% of both preterm and term infants had intrapartum HIV transmission (OR, 0.9; 95% CI, 0.1-6.8).
Preterm delivery was significantly associated with intrapartum HIV transmission among women who used zidovudine during pregnancy or during the perinatal period and among those who had not. The association was also significant when stratifying by markers of the severity of maternal disease.
Intrapartum characteristics. Rupture of fetal membranes (table  1) . Similar associations between the duration of membrane rupture and transmission were observed among vaginal and cesarean deliveries separately, but no independent associations between either intrauterine or intrapartum HIV transmission and mode of delivery were observed. Data were too sparse to classify cesarean deliveries as undertaken before membrane rupture and onset of labor. Other intrapartum variables investigated (duration of labor, episiotomy or perineal lacerations, and internal fetal monitoring) were not associated with intrauterine or intrapartum HIV transmission (data not shown). Severity of maternal disease. Markers of severity of maternal disease were weakly but not significantly associated with transmission in unadjusted analyses (table 1), but after adjustment for zidovudine use the associations were statistically significant. Maternal counts of !500/mL CD4 cells (OR, 2.1; 95% CI, 1.1-4.1), CD4 percentage !29 (OR, 2.3; 95% CI, 1.1-4.7), and clinical symptoms or AIDS (OR, 3.7; 95% CI, 1.6-8.2) were each significantly associated with increased intrapartum HIV transmission adjusting for zidovudine use only. In the full multivariate model, only maternal clinical stage remained significantly associated with intrapartum transmission (table 2) . Intrauterine infection was not increased among women with clinical symptoms or AIDS nor among women with low CD4 T lymphocyte cell counts, percentages, or CD4:CD8 ratios (table 1) nor were there any associations with intrauterine transmission after adjusting for any of the other variables.
Timing of transmission and disease progression in HIV-infected children. HIV-infected children with positive PCR or culture results within the first 2 days of life had a 2-fold higher risk of progression to AIDS or death (RR, 1.9; 95% CI, 0.9-4.2) and a higher overall mortality (RR, 2.3; 95% CI, 0.8-5.2) than infected children with negative results (figure 2). By age 1 year, 43% of intrauterine-infected children had developed AIDS or died compared with 29% of intrapartum-infected children (logrank test, ). Progression to AIDS or death among HIV-P ϭ .12 infected children with positive PCR or culture results within 2 days of birth was significantly increased (RR, 2.5; 95% CI, 1.1-5.8) after adjusting for preterm delivery (RR, 4.3; 95% CI, 1.8-9.9) and low maternal CD4 cell counts (RR, 1.6; 95% CI, 0.7-3.5).
Discussion
Events at the time of delivery cannot influence events that preceded them. Thus, our finding that the duration of membrane rupture prior to delivery was associated with intrapartum but not intrauterine transmission was internally consistent. This is reassuring since the analysis relies on the inference that the results of virus-specific diagnostic tests can be used to identify the timing of transmission. Other attempts to test the validity of the working definition have also shown reasonable internal consistency. For example, modeling time to development of child-specific antibodies to particular HIV proteins estimated that a third of infants were infected before delivery, consistent with estimates based on early PCR results [20] . Children with positive viral cultures in the first week of life had increased percentages of CD8 and HLA-DR ϩ lymphocytes (a marker that appears on lymphocytes shortly after activation) than those with later positive results [21] .
We found strong and significant reductions in intrapartum transmission associated with maternal zidovudine use, suggesting that zidovudine is important in reducing transmission that occurs at delivery. Associations between zidovudine use and intrauterine transmission, although not statistically significant, were consistent with the inference that zidovudine use may also result in some reduction in intrauterine transmission. There was no evidence that the proportion of intrauterine infections was increased among infected children whose mothers used zidovudine. These findings suggest that failure of zidovudine to prevent transmission in some instances cannot simply be accounted for by transmission early in pregnancy. Other mechanisms will need to be investigated if interventions to reduce maternal-infant HIV transmission below thresholds achievable with the standard of care antiretroviral protocol [22] are to be developed.
Preterm delivery has been associated with an increased risk of HIV transmission in this [18] and most of the other large cohort studies [15, [23] [24] [25] [26] . However, it could not be determined from these previous studies whether preterm delivery was a cause or a consequence of HIV transmission. By separating intrauterine from intrapartum infections in this analysis, we observed that preterm infants had a substantially increased risk of intrapartum infection over term infants, but preterm and term infants were equally likely to acquire intrauterine infection. This suggests that intrauterine infection is unlikely to precipitate preterm delivery; rather, preterm infants are at increased risk of acquiring infection at the time of delivery.
The increased risk of intrapartum infection with preterm delivery was restricted to infants delivered following longer rupture of membranes, supporting the notion that preterm infants are more vulnerable to prolonged exposure to HIV at delivery. Vulnerability may be related to immature mucosal barriers or to failure to acquire protective levels of neutralizing antibody, since passive transfer of maternal antibody across the placenta may occur late in pregnancy. The one intervention trial specifically targeting perinatal transmission, using manual cleansing of the birth canal with chlorexidine, found reduced transmission among children born after longer rupture of membranes [27] . Many of these children may also have been born preterm, as premature rupture of membranes is an important initiator of preterm delivery. Current clinical trials and intervention programs may inadvertently exclude many preterm deliveries by recruiting through prenatal clinics. Efforts should be made to ensure that preterm deliveries are included in intervention programs.
We found no evidence that the severity of maternal disease was associated with intrauterine HIV transmission. However, it was associated with intrapartum HIV transmission. Low maternal CD4 T lymphocyte counts have been associated with increased shedding of HIV-infected cells from the cervix and vagina [28, 29] . Thus, markers of the severity of maternal disease may indicate the extent of viral exposure at delivery. Transplacental transmission may require other mechanisms.
We found a 2-fold increase in progression to severe disease or death among HIV-infected children who had virus detected by PCR or culture within the first 2 days of life, supporting the thesis that intrauterine infection has a worse prognosis than intrapartum infection. The association was independent of preterm delivery and severity of maternal disease. (In this analysis, these factors slightly masked the unadjusted association between intrauterine transmission and disease progression, because they were independent risk factors for disease progression and were associated with intrapartum transmission.) Early positivity of virus-specific tests can, however, only partially account for the variability of disease progression observed in HIVinfected children. While more than half (56%) of children with rapidly fatal HIV infections had early positive results, almost a quarter (23%) of those with a less severe course also had positive results.
Early PCR or culture results may capture, in addition to information about the timing of transmission, information about host or viral factors related to viral replication. Children with evidence of early infection have higher median HIV RNA values in the early months of life than children with late infection [30] . Higher levels of HIV RNA in the first 2 months are strongly predictive of poor prognosis [30, 31] . Viral phenotypes with more efficient replication, or that are not curtailed by host immune responses, may reach detectable levels sooner than variants with slower replication [32] . For patient-care purposes, clinicians should recognize that HIV-infected children with early positive PCR or viral culture results are likely to progress more rapidly.
Our results suggest that prevention of preterm delivery, particularly prevention of premature rupture of membranes, may help reduce maternal-infant transmission even in the absence of other interventions. It is, however, a tragic reality of the HIV epidemic in the United States that the women most likely to be infected are also those who are the least well-integrated into primary health care services, and who may have multiple other risk factors for poor reproductive outcomes. The potential to reduce maternal-infant HIV transmission using zidovudine prophylaxis has raised the urgent need for active outreach to identify HIV-infected women and to bring them into medical care early in pregnancy. Possible benefits of good prenatal care in reducing the risk of preterm delivery adds further importance to these efforts.
